Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Bioanalysis ; 4(23): 2769-74, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23216117

ABSTRACT

One hundred and eighty scientists from industry and academia discussed the progress in emerging technologies approaching regulated bioanalysis, with a focus on what potential hurdles prevent them becoming broadly accepted by industry and regulators. The conference delegates agreed that moving innovative technologies forward can only be achieved by providing solid data to support the application. In addition, also establishing an open dialogue with health authorities is key for success. By successfully integrating new technologies in the bioanalytical laboratory we contribute to bringing more safe and efficacious therapies faster to patients.


Subject(s)
Biomarkers/analysis , Belgium , Chromatography, High Pressure Liquid , DNA/genetics , DNA/metabolism , Enzyme-Linked Immunosorbent Assay , Humans , Laboratories/standards , Mass Spectrometry , Metabolomics , Pharmaceutical Preparations/metabolism
2.
Bioanalysis ; 4(6): 627-31, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22452251

ABSTRACT

This conference report provides an overview of the discussions at the 2nd European Bioanalysis Forum (EBF) Focus Meeting 'Large Meets Small' held on 20 and 21 June 2011 in Brussels. The meeting discussed scientific progress in the bioanalysis of peptides and proteins with MS-based techniques. Bioanalytical experts in ligand-binding assays (LBAs) and MS from industry and academia presented at the meeting or joined the discussion. The conference hosted sessions on technology developments, validation requirements, cutting edge (bio)analytical approaches for both proteins and peptides and discussions on the analytical challenge presented by the metabolism of peptides or proteins. The engagement of the scientists as well as the bioanalytical challenges identified were real: by shifting peptide or protein analysis from the LBAs laboratory into the LC-MS laboratory, the bioanalytical scientist is moving into partially uncharted territory. The conference delegates strongly shared the feeling that success in overcoming the challenges of peptide and protein bioanalysis will require further integration of the expertise of LBAs and LC-MS/MS experts.


Subject(s)
Chromatography, Liquid , Mass Spectrometry , Peptides/analysis , Proteins/analysis , Peptides/metabolism , Pharmacokinetics , Proteins/metabolism
3.
Bioanalysis ; 4(6): 633-42, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22452252

ABSTRACT

The 4th Open Symposium of the European Bioanalytical Forum entitled 'Less is More' was held on 16-18 November 2011 at the Hesperia Tower Hotel, Barcelona, Spain. More than 50 interesting presentations were delivered covering areas with interest for the small- and large-molecule community - biomarker validation; regulations, including an update on new and emerging guidelines and on Global harmonization; technology updates; incurred sample stability; microdosing; dried blood spots and microsampling; challenges of 'free' and 'total' macromolecule quantification; stability issues in ligand binding assays or anomalous results. In excess of 450 delegates from more than 170 institutes and companies (industry, regulators and academia) from all global regions participated in the open and stimulating discussions. This manuscript provides an overview of the highlights discussed at the meeting.


Subject(s)
Biomarkers/analysis , Chromatography, Liquid , Dried Blood Spot Testing , Guidelines as Topic , Mass Spectrometry , Pharmacokinetics
4.
J Med Chem ; 47(3): 627-43, 2004 Jan 29.
Article in English | MEDLINE | ID: mdl-14736243

ABSTRACT

A series of novel 3,4-diarylpyrazolines was synthesized and evaluated in cannabinoid (hCB(1) and hCB(2)) receptor assays. The 3,4-diarylpyrazolines elicited potent in vitro CB(1) antagonistic activities and in general exhibited high CB(1) vs CB(2) receptor subtype selectivities. Some key representatives showed potent pharmacological in vivo activities after oral dosing in both a CB agonist-induced blood pressure model and a CB agonist-induced hypothermia model. Chiral separation of racemic 67, followed by crystallization and an X-ray diffraction study, elucidated the absolute configuration of the eutomer 80 (SLV319) at its C(4) position as 4S. Bioanalytical studies revealed a high CNS-plasma ratio for the development candidate 80. Molecular modeling studies showed a relatively close three-dimensional structural overlap between 80 and the known CB(1) receptor antagonist rimonabant (SR141716A). Further analysis of the X-ray diffraction data of 80 revealed the presence of an intramolecular hydrogen bond that was confirmed by computational methods. Computational models and X-ray diffraction data indicated a different intramolecular hydrogen bonding pattern in the in vivo inactive compound 6. In addition, X-ray diffraction studies of 6 revealed a tighter intermolecular packing than 80, which also may contribute to its poorer absorption in vivo. Replacement of the amidine -NH(2) moiety with a -NHCH(3) group proved to be the key change for gaining oral biovailability in this series of compounds leading to the identification of 80.


Subject(s)
Pyrazoles/chemical synthesis , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Sulfonamides/chemical synthesis , Administration, Oral , Animals , Arachidonic Acid/metabolism , Binding, Competitive , Biological Availability , CHO Cells , Cricetinae , Crystallography, X-Ray , Fever/chemically induced , Fever/physiopathology , Humans , Hypotension/chemically induced , Hypotension/physiopathology , Male , Mice , Models, Molecular , Molecular Conformation , Pyrazoles/chemistry , Pyrazoles/pharmacology , Radioligand Assay , Rats , Stereoisomerism , Structure-Activity Relationship , Sulfonamides/chemistry , Sulfonamides/pharmacology
5.
Chem Pharm Bull (Tokyo) ; 50(8): 1109-13, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12192147

ABSTRACT

The design, synthesis and biological activities of potent pyrazole-based tricyclic CB1 receptor antagonists (2) are described. The key synthetic step involves the ring closure of the lithiated alpha, gamma-keto ester adduct (4). The optimal nitroderivative (28) in this series exhibits a high CB1 receptor affinity (pKi=7.2) as well as very potent antagonistic activity (pA2=8.8) in vitro. The regioselectivity of the pyrazole ring closure is shown to depend strongly on the aromatic substitution pattern of the applied arylhydrazine.


Subject(s)
Cannabinoids/chemical synthesis , Cannabinoids/pharmacology , Drug Design , Receptors, Drug/antagonists & inhibitors , Animals , Cannabinoids/chemistry , Rats , Receptors, Cannabinoid
SELECTION OF CITATIONS
SEARCH DETAIL
...